{"id":25478,"date":"2022-09-23T00:44:00","date_gmt":"2022-09-22T16:44:00","guid":{"rendered":"https:\/\/flcube.com\/?p=25478"},"modified":"2025-02-05T01:00:55","modified_gmt":"2025-02-04T17:00:55","slug":"nerviano-medical-sciences-collaborates-with-merck-on-parp1-inhibitor-nms-293","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=25478","title":{"rendered":"Nerviano Medical Sciences Collaborates with Merck on PARP1 Inhibitor NMS-293"},"content":{"rendered":"\n<p>Italy-based Nerviano Medical Sciences S.r.l. (NMS), which is 90% owned by Chinese investment fund SARI under a deal that closed in 2018, has unveiled a collaboration and licensing deal with Germany-based Merck Healthcare KGaA. The agreement grants Merck global rights to develop and commercialize the poly (ADP-ribose) polymerase 1 (PARP1) inhibitor NMS-293. Merck is paying $65 million upfront, with further undisclosed milestone commitments and royalties on future sales. <\/p>\n\n\n\n<p><strong>Drug Overview and Development<\/strong><br>NMS-293 is an orally available small molecule inhibitor of PARP1 and is currently in early clinical development. The drug is being evaluated for the treatment of patients with BRCA mutated tumors as a single agent and in combination with temozolomide (TMZ) for recurrent glioblastoma (GBM).<\/p>\n\n\n\n<p><strong>Background on Nerviano and SARI<\/strong><br>SARI, affiliated with the Shanghai Advanced Research Institute, invested $369 million to acquire a 90% stake in Nerviano in partnership with a group of investors and China-based pharma company Nanjing Hicin Pharmaceutical Co., Ltd (<a href=\"https:\/\/www.google.com\/finance\/quote\/300584:SHE\">SHE: 300584<\/a>). The deal closed in March 2018.<\/p>\n\n\n\n<p><strong>Future Outlook<\/strong><br>The collaboration with Merck Healthcare marks a significant step for Nerviano Medical Sciences in advancing the development of NMS-293. By leveraging Merck&#8217;s global capabilities, the partnership aims to bring this innovative PARP1 inhibitor to patients worldwide, addressing significant unmet needs in the treatment of BRCA mutated tumors and recurrent glioblastoma.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Italy-based Nerviano Medical Sciences S.r.l. (NMS), which is 90% owned by Chinese investment fund SARI&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[16,3548,120,3547,767,3549],"class_list":["post-25478","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-cancer","tag-hicin-pharmaceutical","tag-merck","tag-nerviano-medical-sciences","tag-parp","tag-she-300584"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Nerviano Medical Sciences Collaborates with Merck on PARP1 Inhibitor NMS-293 - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Italy-based Nerviano Medical Sciences S.r.l. (NMS), which is 90% owned by Chinese investment fund SARI under a deal that closed in 2018, has unveiled a collaboration and licensing deal with Germany-based Merck Healthcare KGaA. The agreement grants Merck global rights to develop and commercialize the poly (ADP-ribose) polymerase 1 (PARP1) inhibitor NMS-293. Merck is paying $65 million upfront, with further undisclosed milestone commitments and royalties on future sales.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=25478\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nerviano Medical Sciences Collaborates with Merck on PARP1 Inhibitor NMS-293\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=25478\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2022-09-22T16:44:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-02-04T17:00:55+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=25478#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=25478\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Nerviano Medical Sciences Collaborates with Merck on PARP1 Inhibitor NMS-293\",\"datePublished\":\"2022-09-22T16:44:00+00:00\",\"dateModified\":\"2025-02-04T17:00:55+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=25478\"},\"wordCount\":225,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Cancer\",\"Hicin Pharmaceutical\",\"Merck\",\"Nerviano Medical Sciences\",\"PARP\",\"SHE: 300584\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=25478#respond\"]}],\"copyrightYear\":\"2022\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=25478\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=25478\",\"name\":\"Nerviano Medical Sciences Collaborates with Merck on PARP1 Inhibitor NMS-293 - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2022-09-22T16:44:00+00:00\",\"dateModified\":\"2025-02-04T17:00:55+00:00\",\"description\":\"Italy-based Nerviano Medical Sciences S.r.l. (NMS), which is 90% owned by Chinese investment fund SARI under a deal that closed in 2018, has unveiled a collaboration and licensing deal with Germany-based Merck Healthcare KGaA. The agreement grants Merck global rights to develop and commercialize the poly (ADP-ribose) polymerase 1 (PARP1) inhibitor NMS-293. Merck is paying $65 million upfront, with further undisclosed milestone commitments and royalties on future sales.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=25478#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=25478\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=25478#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nerviano Medical Sciences Collaborates with Merck on PARP1 Inhibitor NMS-293\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Nerviano Medical Sciences Collaborates with Merck on PARP1 Inhibitor NMS-293 - Insight, China&#039;s Pharmaceutical Industry","description":"Italy-based Nerviano Medical Sciences S.r.l. (NMS), which is 90% owned by Chinese investment fund SARI under a deal that closed in 2018, has unveiled a collaboration and licensing deal with Germany-based Merck Healthcare KGaA. The agreement grants Merck global rights to develop and commercialize the poly (ADP-ribose) polymerase 1 (PARP1) inhibitor NMS-293. Merck is paying $65 million upfront, with further undisclosed milestone commitments and royalties on future sales.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=25478","og_locale":"en_US","og_type":"article","og_title":"Nerviano Medical Sciences Collaborates with Merck on PARP1 Inhibitor NMS-293","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=25478","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2022-09-22T16:44:00+00:00","article_modified_time":"2025-02-04T17:00:55+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=25478#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=25478"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Nerviano Medical Sciences Collaborates with Merck on PARP1 Inhibitor NMS-293","datePublished":"2022-09-22T16:44:00+00:00","dateModified":"2025-02-04T17:00:55+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=25478"},"wordCount":225,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Cancer","Hicin Pharmaceutical","Merck","Nerviano Medical Sciences","PARP","SHE: 300584"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=25478#respond"]}],"copyrightYear":"2022","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=25478","url":"https:\/\/flcube.com\/?p=25478","name":"Nerviano Medical Sciences Collaborates with Merck on PARP1 Inhibitor NMS-293 - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2022-09-22T16:44:00+00:00","dateModified":"2025-02-04T17:00:55+00:00","description":"Italy-based Nerviano Medical Sciences S.r.l. (NMS), which is 90% owned by Chinese investment fund SARI under a deal that closed in 2018, has unveiled a collaboration and licensing deal with Germany-based Merck Healthcare KGaA. The agreement grants Merck global rights to develop and commercialize the poly (ADP-ribose) polymerase 1 (PARP1) inhibitor NMS-293. Merck is paying $65 million upfront, with further undisclosed milestone commitments and royalties on future sales.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=25478#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=25478"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=25478#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Nerviano Medical Sciences Collaborates with Merck on PARP1 Inhibitor NMS-293"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/25478","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=25478"}],"version-history":[{"count":2,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/25478\/revisions"}],"predecessor-version":[{"id":25482,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/25478\/revisions\/25482"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=25478"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=25478"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=25478"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}